Malathion Shortage: What Providers and Prescribers Need to Know in 2026

Patients with treatment-resistant head lice represent a small but consistent portion of pediatric and primary care visits. Malathion 0.5% lotion (Ovide) remains an important second-line option in the pediculicide armamentarium — but providers increasingly report that their patients struggle to fill this prescription. This guide covers what clinicians need to know about malathion availability in 2026 and how to best support patients navigating this challenge.

Current Availability Status: Not a Formal Shortage

As of 2026, malathion is not on the FDA's official drug shortage database. The manufacturer (Taro Pharmaceuticals) continues to produce the product. However, the practical access challenges your patients face are real: most community pharmacies do not routinely stock malathion, creating a de facto availability problem even without a formal shortage designation.

Understanding the structural reasons for this helps providers counsel patients effectively and set realistic expectations at the point of prescribing.

Why Pharmacies Don't Routinely Stock Malathion

Low, unpredictable demand: Malathion is used only when first-line treatments fail, limiting prescribing volume. Most pharmacies fill only a handful of prescriptions per year.

Flammability and storage: The 78% isopropyl alcohol vehicle makes malathion a Class IB flammable liquid. Some pharmacies — particularly smaller community sites — are reluctant to manage the associated storage requirements.

Inventory cost: At ~$250-$260 per 59 mL bottle, malathion ties up significant inventory capital relative to its low and unpredictable turnover.

Clinical Context: Who Is Malathion Appropriate For?

Per FDA labeling, malathion is indicated for treatment of Pediculus humanus capitis (head lice and their ova) in patients 6 years of age and older. It is contraindicated in neonates and infants due to increased scalp permeability. The American Academy of Pediatrics (AAP) and CDC recognize it as an effective second-line option when first-line agents fail or pyrethroid resistance is suspected.

Key clinical features of malathion that distinguish it from first-line agents:

Dual mechanism: both pediculicidal AND ovicidal — particularly important in cases with high egg burden

Organophosphate mechanism of action — effective against pyrethroid-resistant lice strains

Residual binding: malathion binds to hair and provides some residual protection after therapy

Single treatment often sufficient; retreat only if live lice persist at 7-9 days

Key Safety Counseling Points for Prescribers

When prescribing malathion, ensure patients understand:

Flammability risk: The lotion and wet hair must not be exposed to open flames, electric heat sources (hair dryers, curling irons), or cigarettes. This must be communicated clearly to parents of children being treated.

Application time: 8-12 hours; most patients apply at bedtime and shampoo out in the morning. Hair must air-dry naturally.

Chemical burn risk: Chemical burns including second-degree burns have been reported. If skin irritation occurs, patients should discontinue use and contact the office.

Household treatment: All household members should be checked for infestation and treated if positive.

Alternatives When Malathion Is Unavailable

When malathion cannot be obtained, the following prescription alternatives offer comparable or superior convenience:

Spinosad 0.9% (Natroba): Ovicidal; single 10-minute application; approved age 4+; not flammable. Often preferred by patients due to shorter contact time.

Ivermectin 0.5% lotion (Sklice): Single 10-minute application; no nit combing required; approved age 6 months+.

Benzyl alcohol 5% (Ulesfia): Two applications, 7 days apart; not ovicidal; approved age 6 months+.

Oral ivermectin (off-label): 400 mcg/kg, two doses 7-10 days apart. Not for patients under 15 kg or in pregnancy.

How to Help Patients Find Malathion

If you choose to prescribe malathion, you can improve fill rates by counseling patients to: call large chain pharmacies (CVS, Walgreens, Walmart Pharmacy) first, ask if the pharmacy can order within 24-48 hours, or try mail-order pharmacies. Your office can also direct patients to medfinder for providers, which contacts pharmacies on the patient's behalf to find where their medication is available.